Disease or development: oxidative stress in the pediatric kidney-brain axis
Abstract
Details
- Title: Subtitle
- Disease or development: oxidative stress in the pediatric kidney-brain axis
- Creators
- Emily J. Steinbach-Swehla
- Contributors
- Lyndsay A. Harshman (Advisor)Douglas R. Spitz (Advisor)Joseph J. Cullen (Committee Member)Vincent A. Magnotta (Committee Member)Dao-Fu Dai (Committee Member)Jennifer G. Jetton (Committee Member)Timothy R. Koscik (Committee Member)
- Resource Type
- Dissertation
- Degree Awarded
- Doctor of Philosophy (PhD), University of Iowa
- Degree in
- Biomedical Science (Free Radical and Radiation Biology)
- Date degree season
- Summer 2022
- DOI
- 10.25820/etd.006636
- Publisher
- University of Iowa
- Number of pages
- xxii, 146 pages
- Copyright
- Copyright 2022 Emily J. Steinbach-Swehla
- Language
- English
- Description illustrations
- illustrations
- Description bibliographic
- Includes bibliographical references (pages 129-146).
- Public Abstract (ETD)
Chronic kidney disease (CKD) affects millions of people worldwide- not just adults, but children as well. Long-term kidney disease in children has been associated with a variety of health concerns including disrupted physical growth, increased psychosocial issues, and lower academic achievement. While dialysis and kidney transplant can treat CKD, this disease remains incurable and the need for discovering preventative treatments of disease progression, such as chemotherapy (cisplatin) CKD is critical.
This thesis will describe a kidney cell model of cisplatin-induced oxidative stress linked to cell death and clinical kidney dysfunction. Use of a novel therapeutic, GC4419 (avasopasem manganese), eliminated kidney injury due to oxidative stress after cisplatin and increased kidney cell survival. In a phase 2b trial of GC4419, those who received 90 mg had significantly better kidney function two years after cisplatin chemotherapy compared to those who did not receive GC4419 and had kidney functions measuring in ≥ stage 3 CKD.
Children who also receive cisplatin chemotherapy are not only at risk for CKD, but also the developmental disruptions associated with kidney dysfunction. Children, adolescents, and young adults treated with cisplatin show a continual decline of kidney function. By the average age of 30, this population has lost an average of 48.5% of their total kidney function measuring in stage 2 CKD. Lifelong battles with CKD, such as this, were also shown to pose a significant risk to the developing brain. Through MRI, we show that CKD associated brain deviances are suggestive of aberrant oxidative stress within the kidney. These findings not only provide a link to the “kidney-brain axis” but also provide a possible therapeutic target for mitigating changes in the pediatric CKD brain.
- Academic Unit
- Biomedical Science Program
- Record Identifier
- 9984285345902771